Wednesday, July 1, 2009

Morphotek working with Synageva BioPharma

The Philadelphia Business Journal reports that Morphotek Inc. said Wednesday that it will collaborate with Synageva BioPharma Corp. on the development of therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Terms were not disclosed.

Exton, Pa.-based Morphotek, a subsidiary of Eisai Corp. of North America, said Synageva will use its proprietary Synageva Expression Platform.

Morphotek specializes in developing treatments for cancer, inflammation and infectious disease.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment